6090 — Human Metabolome Technologies Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMicro CapNeutral

Annual income statement for Human Metabolome Technologies, fiscal year end - June 30th, JPY millions except per share, conversion factor applied.

	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th	2025 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,124	1,223	1,299	1,346	1,455
Cost of Revenue
Gross Profit	806	840	860	869	922
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,094	1,023	1,084	1,105	1,177
Operating Profit	30	200	215	241	278
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	50.9	262	237	262	270
Provision for Income Taxes
Net Income After Taxes	58.2	268	286	243	256
Net Income Before Extraordinary Items
Net Income	58.2	268	286	243	256
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	58.2	268	286	243	256
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	10.8	44.4	47.9	37.9	39
Dividends per Share